Inhibitor of p110? PI3K. It decreases infiltration of leukocytes into the CNS in EAE models and suppresses chemotactic responses of eosinophils to platelet activating factor. (C08-0489-409)

Catalog No.: C08-0489-409
Mfr. No.: A7202-10 mg
Mfr. Name: LKT Laboratories, Inc
Qty/UOM: 1
UOM: EA

Price: $703.19

List Price: $781.32

AS-604850 is an inhibitor of p110&gamma PI3K that exhibits anti-inflammatory and immunosuppressive activities. In animal models of experimental autoimmune encephalitis (EAE), AS-604850 decreases the number of leukocytes infiltrated into the CNS and

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

AS-604850 is an inhibitor of p110γ PI3K that exhibits anti-inflammatory and immunosuppressive activities. In animal models of experimental autoimmune encephalitis (EAE), AS-604850 decreases the number of leukocytes infiltrated into the CNS and ameliorates disease symptoms. AS-604850 also decreases chemotactic responses of eosinophils to platelet activating factor (PAF).

UPC:: 51152100
Condition:: New
Availability:: 3 Days
Weight:: 1.00 Ounces
HazmatClass:: No
WeightUOM:: LB
MPN:: A7202-10 mg
CAS:: 48449-76-7

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."